ArticleCureus2025
Reversible Thyroid Dysfunction Associated With Quetiapine Use in an Adolescent Patient: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypothyroidism frequently manifests with neuropsychiatric symptoms that may overlap with primary psychiatric disorders. Quetiapine, an atypical antipsychotic commonly used in mood and psychotic disorders, is generally well tolerated but has been associated with metabolic disturbances and, less commonly, thyroid dysfunction such as subclinical hypothyroidism. We report the case of an adolescent female treated with quetiapine for mood instability and suicidality, who developed elevated thyroid-stimulating hormone (TSH) levels and dyslipidemia despite remaining clinically euthyroid. Dose reduction and eventual discontinuation of quetiapine led to normalization of thyroid function and lipid profile, while psychiatric stability was maintained. Possible mechanisms for quetiapine-induced thyroid dysfunction include dopamine receptor antagonism affecting TSH regulation, direct thyroid effects, and metabolic changes related to weight gain. This case highlights the necessity for routine monitoring of thyroid and metabolic parameters during quetiapine therapy to ensure optimal management of psychiatric symptoms while minimizing endocrine complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.